CA2602794A1 - Stannsoporfin compositions and administration - Google Patents

Stannsoporfin compositions and administration Download PDF

Info

Publication number
CA2602794A1
CA2602794A1 CA002602794A CA2602794A CA2602794A1 CA 2602794 A1 CA2602794 A1 CA 2602794A1 CA 002602794 A CA002602794 A CA 002602794A CA 2602794 A CA2602794 A CA 2602794A CA 2602794 A1 CA2602794 A1 CA 2602794A1
Authority
CA
Canada
Prior art keywords
stannsoporfin
pharmaceutical composition
solution
magnesium
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002602794A
Other languages
English (en)
French (fr)
Inventor
Philip C. Lang
George S. Drummond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infacare Pharmaceutical Corp
Original Assignee
Infacare Pharmaceutical Corporation
Philip C. Lang
George S. Drummond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/096,359 external-priority patent/US20060222668A1/en
Application filed by Infacare Pharmaceutical Corporation, Philip C. Lang, George S. Drummond filed Critical Infacare Pharmaceutical Corporation
Publication of CA2602794A1 publication Critical patent/CA2602794A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002602794A 2005-04-01 2006-03-31 Stannsoporfin compositions and administration Abandoned CA2602794A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/096,359 US20060222668A1 (en) 2005-04-01 2005-04-01 Stannsoporfin compositions, drug products and methods of manufacture
US11/096,359 2005-04-01
US11/239,769 2005-09-30
US11/239,769 US20060222669A1 (en) 2005-04-01 2005-09-30 Stannsoporfin compositions and administration
PCT/US2006/012185 WO2006107806A2 (en) 2005-04-01 2006-03-31 Stannsoporfin compositions and administration

Publications (1)

Publication Number Publication Date
CA2602794A1 true CA2602794A1 (en) 2006-10-12

Family

ID=37073987

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002602794A Abandoned CA2602794A1 (en) 2005-04-01 2006-03-31 Stannsoporfin compositions and administration

Country Status (6)

Country Link
EP (1) EP1865777A4 (de)
KR (1) KR20080004531A (de)
AU (1) AU2006232330A1 (de)
CA (1) CA2602794A1 (de)
NO (1) NO20075508L (de)
WO (1) WO2006107806A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375216B2 (en) 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
CN104116745B (zh) 2006-10-04 2018-07-06 婴儿护理药品公司 包含锡泊芬的组合物
DK2691398T3 (en) 2011-03-30 2017-01-16 Infacare Pharmaceutical Corp Methods for synthesizing metal mesoporphyrins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692440A (en) * 1985-03-25 1987-09-08 The Rockefeller University Therapeutic use of tin mesoporphyrin
US4657902A (en) * 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
US7375216B2 (en) * 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
US20040097481A1 (en) * 2002-11-20 2004-05-20 Benjamin Levinson Water-soluble mesoporphyrin compounds and methods of preparation

Also Published As

Publication number Publication date
KR20080004531A (ko) 2008-01-09
EP1865777A2 (de) 2007-12-19
AU2006232330A1 (en) 2006-10-12
EP1865777A4 (de) 2008-07-16
WO2006107806A2 (en) 2006-10-12
WO2006107806A3 (en) 2007-07-12
NO20075508L (no) 2007-10-31

Similar Documents

Publication Publication Date Title
KR100735788B1 (ko) 일반 염을 함유하는 목시플록사신 제형
US20080261939A1 (en) Stannsoporfin compositions and administration
US8450356B2 (en) Pharmaceutical composition
CA2602794A1 (en) Stannsoporfin compositions and administration
WO2019162892A1 (en) Stable injectable compositions of epinephrine
WO2012013117A1 (zh) 含维生素c或其衍生物的替莫唑胺药物组合物及其制备方法
CN102949339B (zh) 一种含有罗库溴铵的注射剂
AU2001260935B2 (en) Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
CN110664747A (zh) 一种盐酸阿比多尔的注射液剂型及其制备方法
JPH021126B2 (de)
CN115518035B (zh) 一种酮咯酸液体组合物、其制备方法及应用
US20030065035A1 (en) Novel stilbene derivative crystal and method for producing the same
AU2016204616A1 (en) Sodium nitrite-containing pharmaceutical compositions
KR20220062368A (ko) p-보로노페닐알라닌을 함유하는 주사액제의 석출 방지 방법
KR20220062367A (ko) p-보로노페닐알라닌을 함유하는 주사액제
CN113559261A (zh) 一种硼携带剂注射剂
TWI619716B (zh) 含維生素ｃ或其衍生物的替莫唑胺醫藥組成物及其製備方法
CN113350271A (zh) 一种质子泵抑制剂的组合物及其制备方法
JP2008255115A (ja) エルゴリン化合物の安定化された水溶液

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20121004